3 New Strong Buy Ratings from Top-Rated Analysts: 09/19/2025

Just what you need before the weekend — a few great stock picks. Here are the latest entries from our Strong Buy Stocks from Top Wall Street Analysts screener:

• Kontoor Brands (KTB): Wrangler & Lee parent crushed Q2 with a double beat.  
• Travere Therapeutics (TVTX) is a rare-disease biotech with a first-in-class kidney drug. Analysts see ~57% upside and a 2026 FDA decision could be the next rocket fuel.
• Myr Group (MYRG) proves that power grid modernization = steady growth.  

P.S. Want more stocks chosen for you? Check out Zen Investor.

1. Kontoor Brands (NYSE: KTB) 

Kontoor Brands owns not one, but two flagship denim labels — Wrangler and Lee. Even though recent trade disputes have had an effect on the company’s business, it still managed to deliver a double beat in Q2 of 2025. The company’s disciplined inventory management, focus on direct-to-consumer (DTC) channels, and growing popularity overseas provide solid growth prospects that are increasingly being recognized by Wall Street. 

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $81.55 — get current quote > 

Max 1-year forecast: $100.00 

Why we’re watching:

• At present, 5 Wall Street analysts track Kontoor Brands and issue ratings for the stock. Their coverage is split between 4 Strong Buys and 1 Hold ratings. See the ratings
• The average price target for KTB shares stands at $89.60, a figure that implies a decent 11.9% upside.
• Ike Boruchow of Wells Fargo (a top 4% rated analyst) recently maintained a Strong Buy rating on KTB, and hiked his price target from $90 to a Street-high $100.   
• Kontoor Brands is the top-rated stock in the Apparel Manufacturing industry, which has an Industry Rating of A.
• KTB currently ranks in the 96th percentile of the equities that we track, giving it a Zen Rating of B.
• In terms of its Financials Component Grade rating, Kontoor Brands shares rank in the 82nd percentile of stocks.
• KTB is currently trading at an attractive price-to-earnings (P/E) ratio of 17.71x — the stock ranks in the top 13% when it comes to Value.
• On top of positive analyst coverage, 34.47% of the insider transactions tied to Kontoor Brands in the past 12 months have been stock purchases. With regard to Sentiment, KTB ranks in the top 10% of equities. (See all 7 Zen Component Grades here >)

2. Travere Therapeutics (NASDAQ: TVTX) 

Our next pick is a biopharma company that has been in business since 2008. Travere Therapeutics focuses on treating rare diseases — chiefly related to nephrology and metabolic disorders. One of its leading products has recently become the first non-immunosuppressive therapy approved for a certain type of nephropathy — and Wall Street has high expectations for TVTX going forward.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $22.82 — get current quote > 

Max 1-year forecast: $47.00 

Why we’re watching:

• Travere Therapeutics enjoys broad, bullish coverage from Wall Street analysts. The stock currently has 5 Strong Buy ratings, 4 Buy ratings, and 1 Hold rating. See the ratings
• In addition, the average price target for TVTX, currently pegged at $35.70, implies a very hefty 56.79% upside. 
• Wells Fargo equity researcher Mohit Bansal (a top 18% rated analyst) recently maintained a Strong Buy rating on the stock and increased his price target from $27 to $35.
• Bansal attributed their price target hike on Travere Therapeutics to "increased confidence in focal segmental glomerulosclerosis approval.
• "IgAN momentum provides additional support," the analyst continued, "but the next critical catalyst and inflection point could be the 2026/01/13 PDUFA for FSGS."
• At present, TVTX ranks in the 89th percentile of the stocks that we track, giving it a Zen Rating of B.
• In terms of its Value Component Grade rating, the stock ranks in the top 29% of equities.
• Sentiment is another strong suit — here, Travere Therapeutics ranks in the 88th percentile of stocks.
• With that being said, Growth is TVTX’s greatest strength — in this category, it ranks in the 97th percentile. (See all 7 Zen Component Grades here >)

3. Myr Group (NASDAQ: MYRG)

Myr Group is a specialty contractor that builds and maintains electrical infrastructure across the U.S. and Canada. Its main focuses are high-voltage power lines, substations, and electrical work for large-scale industrial projects. With electrification showing no signs of stopping — coupled with constant calls for grid modernization, MYRG is set to benefit from steady demand. 

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $176.99 — get current quote > 

Max 1-year forecast: $211.00 

Why we’re watching:

• Myr Group shares are a consensus Buy per Wall Street analysts. The stock currently has 3 Strong Buy ratings, 1 Buy rating, and 3 Hold ratings. See the ratings  
• The average 12-month price forecast for the stock currently sits at $192.86, and implies a 9.68% upside.
• KeyBanc researcher Sangita Jain (a top 8% rated analyst) maintained a Strong Buy rating on MYRG after the company’s Q2 2025 earnings call, and increased her price target from $205 to a Street-high $211. 
• Jain said the "strong" results were highlighted by consensus-beating EPS.
• The quarter generated previously indicated mid-to-high-single-digit core revenue growth in both segments in 2H 2025, the analyst continued, with decent project bookings momentum in both segments.
• The stock price has responded favorably to improved execution and a lower-risk MSA-driven project profile, Jain said, looking ahead.
• Myr Group is the 2nd highest-rated stock in the Engineering & Construction industry, which has an Industry Rating of A.
• MYRG currently ranks in the top 1% of the equities that we track. To be more precise, it is rated 32nd overall out of roughly 4,600 stocks — giving it a Zen Rating of A.
• Myr Group shares rank in the 77th percentile in terms of three Component Grade ratings — Value, Sentiment, and Financials. 
• When it comes to Artificial Intelligence, MYRG ranks in the 78th percentile of stocks.
• The stock has surged by 47.07% in the past six months — so it’s no wonder that it ranks in the top 17% with regard to Momentum.
• However, Growth is the star of the show here — as MYRG ranks in the top 1% of equities in this category. (See all 7 Zen Component Grades here >)

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.